High sensitivity of asymmetric 18F-THK5351 PET abnormality in patients with corticobasal syndrome

被引:3
|
作者
Kurihara, Masanori [1 ,2 ]
Ishibashi, Kenji [3 ]
Matsubara, Tomoyasu [1 ]
Hatano, Keiko [1 ]
Ihara, Ryoko [1 ]
Higashihara, Mana [1 ]
Kameyama, Masashi [3 ,4 ]
Tokumaru, Aya Midori [4 ]
Takeda, Katsuhiko [1 ,5 ]
Nishina, Yasushi [1 ]
Kanemaru, Kazutomi [1 ]
Ishii, Kenji [3 ]
Iwata, Atsushi [1 ,2 ]
机构
[1] Tokyo Metropolitan Inst Geriatr & Gerontol, Dept Neurol, 35-2 Sakaecho,Itabashi Ku, Tokyo 1730015, Japan
[2] Tokyo Metropolitan Inst Geriatr & Gerontol, Integrated Res Initiat Living Well Dementia, Tokyo, Japan
[3] Tokyo Metropolitan Inst Geriatr & Gerontol, Res Team Neuroimaging, Tokyo, Japan
[4] Tokyo Metropolitan Inst Geriatr & Gerontol, Dept Diagnost Radiol, Tokyo, Japan
[5] Bunkyo Cognit Neurosci Lab, Tokyo, Japan
基金
日本学术振兴会;
关键词
MONOAMINE-OXIDASE-B; NEUROPATHOLOGIC CRITERIA; STRUCTURAL MRI; DEGENERATION; DIAGNOSIS; PATHOLOGY;
D O I
10.1038/s41598-023-39227-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Corticobasal syndrome (CBS) is characterized by symptoms related to the asymmetric involvement of the cerebral cortex and basal ganglia. However, early detection of asymmetric imaging abnormalities can be challenging. Previous studies reported asymmetric F-18-THK5351 PET abnormalities in CBS patients, but the sensitivity for detecting such abnormalities in larger patient samples, including early-stage cases, remains unclear. Patients clinically diagnosed with CBS were recruited. All patients displayed asymmetric symptoms in the cerebral cortex and basal ganglia. Asymmetric THK5351 PET abnormalities were determined through visual assessment. Brain MRI, perfusion SPECT, and dopamine transporter (DAT) SPECT results were retrospectively reviewed. The 15 patients had a median age of 72 years (59-86 years) and a disease duration of 2 years (0.5-7 years). Four patients met the probable and 11 met the possible CBS criteria according to Armstrong criteria at the time of PET examination. All patients, including early-stage cases, exhibited asymmetric tracer uptake contralateral to their symptom-dominant side in the cerebral cortex/subcortical white matter and striatum (100%). The sensitivity for detecting asymmetric imaging abnormalities contralateral to the symptom-dominant side was 86.7% for brain MRI, 81.8% for perfusion SPECT, and 90% for DAT SPECT. White matter volume reduction was observed in the subcortical region of the precentral gyrus with increased THK5351 uptake, occurring significantly more frequently than gray matter volume reduction. THK5351 PET may be a sensitive imaging technique for detecting asymmetric CBS pathologies, including those in early stages.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351 (vol 43, pg 2211, 2016)
    Harada, Ryuichi
    Furumoto, Shozo
    Tago, Tetsuro
    Furukawa, Katsutoshi
    Ishiki, Aiko
    Tomita, Naoki
    Iwata, Ren
    Tashiro, Manabu
    Arai, Hiroyuki
    Yanai, Kazuhiko
    Kudo, Yukitsuka
    Okamura, Nobuyuki
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 177 - 177
  • [32] Brain PET Imaging of 11C-Methionine, 18F-FDG, and 18F-THK5351 in a Case of Lymphomatoid Granulomatosis
    Higashihara, Mana
    Ishibashi, Kenji
    Tokumaru, Aya M.
    Ishii, Kenji
    Iwata, Atsushi
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (12) : E749 - E751
  • [33] Author Correction: 18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
    Jung-Lung Hsu
    Shih-Hsin Chen
    Ing-Tsung Hsiao
    Chin-Song Lu
    Tzu-Chen Yen
    Nobuyuki Okamura
    Kun-Ju Lin
    Yi-Hsin Weng
    Scientific Reports, 11
  • [34] Visualization of Motor Cortex Involvement by 18F-THK5351 PET Potentially Strengthens Diagnosis of Amyotrophic Lateral Sclerosis
    Saitoh, Yuji
    Imabayashi, Etsuko
    Mukai, Taiji
    Matsuda, Hiroshi
    Takahashi, Yuji
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (03) : 243 - 245
  • [35] Increased 18F-THK5351 Uptake at Bilateral Primary Motor Cortex in Patients with Progressive Pseudobulbar Palsy
    Takahashi, Kensuke
    Kurihara, Masanori
    Ishibashi, Kenji
    Komori, Yuta
    Goto, Ryoji
    Higashihara, Mana
    Kameyama, Masashi
    Hirano, Hirohiko
    Maeda, Meiko Hashimoto
    Watanabe, Rie
    Ishii, Kenji
    Iwata, Atsushi
    ACTA NEUROLOGICA SCANDINAVICA, 2024, 2024
  • [36] To tau or to MAO-B? Most of the 18F-THK5351 signal is blocked by selegiline
    Villemagne, Victor
    Dore, Vincent
    Okamura, Nobuyuki
    Baxendale, David
    Harada, Ryuichi
    Mulligan, Rachel
    Furumoto, Shozo
    Salvado, Olivier
    Yanai, Kazuhiro
    Masters, Colin
    Rowe, Christopher
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [37] Distribution Pattern of the Monoamine Oxidase B Ligand, 18F-THK5351, in the Healthy Brain
    Ishibashi, Kenji
    Miura, Yoshiharu
    Tago, Tetsuro
    Toyohara, Jun
    Higashihara, Mana
    Iwata, Atsushi
    Ishii, Kenji
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (07) : E489 - E495
  • [38] Increased Uptake of 18F-THK5351 in Glioblastoma But Not in Primary Central Nervous System Lymphoma
    Mitamura, Katsuya
    Norikane, Takashi
    Yamamoto, Yuka
    Miyake, Keisuke
    Nishiyama, Yoshihiro
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : 772 - 773
  • [39] Potential Use of 18F-THK5351 PET to Identify Wallerian Degeneration of the Pyramidal Tract Caused by Cerebral Infarction
    Ishibashi, Kenji
    Kameyama, Masashi
    Tago, Tetsuro
    Toyohara, Jun
    Ishii, Kenji
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (12) : E523 - E524
  • [40] Increased Uptake of 18F-THK5351 in Isocitrate Dehydrogenase-Wildtype Glioblastoma But Not in Meningioma
    Mitamura, Katsuya
    Norikane, Takashi
    Yamamoto, Yuka
    Miyake, Keisuke
    Nishiyama, Yoshihiro
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (10) : 962 - 963